Breast Cancer Thought Leaders Differentiate Development Compounds in New MedPredict Report

Share Article

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report in its oncology series entitled “Thought Leader Insight & Analysis: Breast Cancer,” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.

MedPredict interviewed renowned North American and European breast cancer thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs.

“This report summarizes the perspectives of six world-class experts in the treatment of breast cancer,” according to MedPredict President Dr. Jeffrey Berk. “They provide their opinions on standards of care today and their expectations for experimental therapeutics. The Panel deals with a number of issues of importance to companies trying to differentiate their new drugs within a very crowded space, including strategies and clinical trial designs that will help to leapfrog more advanced competitors. They reveal the key indications worth pursuing, and the classes of drugs that can produce meaningful survival advantages for women with these breast cancers.”

Mechanisms/targets discussed in this report include: Angiogenesis inhibitors (VEGF / PDGF /FGF / VDA) , Antiresorptives, Antimitotics, Bcl2, glycoprotein NMB (GPNMB), HER2, HER2/EGFR, HER3, IGF1, MEK, PARP, PI3K / mTOR / AKT, WT1.

Companies/Partnerships included in this report: Abbott (ABT-737, ABT-888), Abraxis (Abraxane), Amgen (Prolia, AMG-479), AstraZeneca (olaparib, AZD-6244, AZD-8055), Bayer Schering Pharma (Bonefos), Bayer Schering/Onyx (Nexavar), BiPar/Sanofi-Aventis (BSI-201), Bristol-Myers Squibb (Ixempra), Celldex (CDX-011), Cell Therapeutics (Xyotax), Eisai (Eribulin), Exelixis/Sanofi-Aventis (XL-765, XL-147), Genentech (Avastin, Herceptin, Omnitarg, Genentech/ImmunoGen (trastuzumab-DM1), GlaxoSmithKline (Tykerb, 1120212, 690693), Merck (dalotuzumab, MK-4827, MK-2206), Merck/Ariad (ridaforolimus, deforolimus, MK-8806, AP-23573), Novartis (Zometa, BEZ-235, BGT-226, everolimus), Pfizer (Sutent, neratinib, figitumumab, AGO14699), Roche (Xeloda), and Sanofi-Aventis/Merrimack (MM-121).

The full report can be purchased by contacting MedPredict.

About MedPredict
MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

For more information contact:
Elizabeth Mathews


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Elizabeth Mathews
(513) 271-1924
Email >
Visit website